Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data published in The New England Journal of Medicine. In ...

“We are very pleased that we can offer Tecentriq as a new treatment for unresectable alveolar soft part sarcoma in adults and children over 2 years. This very rare disease, which occurs most often in ...

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2023 / 01 / 230104085312.htm ...